All posts

5N Plus is undervalued, Laurentian Bank Securities says

With its fourth quarter 2017 results coming in above consensus, investors can feel positive about 5N Plus Inc. (5N Plus Stock Quote, Chart, News: TSX:VNP), says analyst Nick Agostino with Laurentian Bank Securities, who rates VNP as a “Buy” with a target price of $3.60.

On Wednesday, specialty chemicals and engineered materials company 5N Plus reported its results for Q4/17 and fiscal year ended December 31, 2017, with adjusted EBITDA and EBITDA for the year hitting $25.1 million (USD) and $26.9 million, respectively, compared to $20.1 million and $15.1 million in 2016. For the quarter, adjusted EBITDA and EBITDA were $6.1 million and $4.4 million, respectively, which compares to $4.3 million and $4.8 million in 2016.

President and CEO Arjang Roshan says that the company is progressing well with regards to its five-year strategic plan.

“The end of 2017 marks the second, and a full year, under 5N21,” said Roshan in a press release. “Thus far, our performance is driven by the execution of the plan’s short‐term objectives, mainly related to optimizing core businesses and global assets. The outcome can be summarized by significant growth in profitability, enhancement in quality of earnings and reduction of earnings volatility. Consequently, return on capital employed has improved markedly and we have continued to strengthen our balance sheet aided by recurrent cashflows.”

For Agostino, numbers of note in the quarterly results were sales, which at $52.5 million (USD) came in at about five per cent above his estimates and about two per cent above consensus, and the adjusted EBITDA, which beat his above-consensus estimate of $5.8 million.

The Montreal-based company has a healthy balance sheet and very low leverage, says the analyst, with net debt at $11.4 million.

Agostino rates VNP a “Buy” with a one-year target price of $3.60, based on 7.5x 2018/2019E EBITDA, representing a 32.8 per cent return at time of publication.

Tagged with: vnp
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Ambarella wins price target raise at Roth

Roth Capital Markets analyst Suji Desilva raised his price target for Ambarella (Ambarella Stock Quote, Chart, News, Analysts, Financials NASDAQ:AMBA)… [Read More]

10 hours ago

Novo Nordisk is undervalued, this fund manager says

Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, told BNN Bloomberg’s Market Call on Aug.… [Read More]

11 hours ago

The risk-to-return on NTG Clarity Networks is incredible, Beacon Securities says

Beacon Securities analyst Doug Cooper maintained a “Buy” rating and $5.00 target for NTG Clarity Networks (NTG Clarity Networks Stock… [Read More]

11 hours ago

NervGen Pharma price target chopped at Research Capital

Research Capital analyst Andre Uddin lowered his target price for NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials… [Read More]

11 hours ago

Theralase Technologies is very undervalued, this analyst says

Research Capital analyst Andre Uddin maintained a “Speculative buy” rating and C$0.70 target price on Theralase Technologies (Theralase Technologies Stock… [Read More]

11 hours ago

Sabio Q2 gets thumbs up at Paradigm Capital

Paradigm Capital analyst Daniel Rosenberg reiterated a “Buy” rating and C$1.50 target price on Sabio Holdings (Sabio Holdings Stock Quote,… [Read More]

4 days ago